Enrolled patients were randomized to either switching to LdT ( 600 mg/d orally ) plus ADV ( 10 mg/d orally ) ( LdT + ADV group ) or to continuation with LAM ( 100 mg/d orally ) plus ADV ( 10 mg/d orally ) ( LAM + ADV group ) , and were followed for 48 wk .